Videos / Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler
In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).
This educational activity was developed by Healthed at the request of and with funding from GSK.
PM-AU-FVU-OGM-220003 approved June 2022

Rosacea – Smarter Diagnosis and State of the Art Care

The Role of SGLT2 Inhibitors in Preventing Dialysis

Syphilis is on the Rise – What GPs Can do to Turn it Around

COPD Cases